martes, 12 de mayo de 2015

NCTR Publications > NCTR Research Highlights

NCTR Publications > NCTR Research Highlights

National Center for Toxicological Researh log with FDA on left side

Current Highlight from May 8, 2015

The Potential of Magnetic Resonance Imaging (MRI) to Follow the Development of Neurotoxicity
NCTR and CDER scientists demonstrated correlation between quantitative T2 mapping, a parameter of the MRI experiment, and the standard pathology procedures used to evaluate neurotoxicity.  Results of MRI and pathology were evaluated at time 0 (untreated) and at 2, 24, and 48 hours. following treatment with kainic acid.  No T2 changes or changes in pathology morphology were detected at 2 hours; however, statistically significant changes were detected by MRI at 24 and 48 hours in agreement with pathology.  The T2 mapping technique is both quantitative and easily completed, showing its strength as a potential source for evaluation as a non-invasive biomarker of effect.  Furthermore, each MRI subject can serve as its own control and be monitored through time, which helps account for individual variability in response encountered even within surrogate inbred animal models of disease and toxicity.  A manuscript describing this study is available online at Toxicological Sciencesdisclaimer icon.
For additional information, please contact Serguei Liachenko, Ph.D., Division of Neurotoxicology, FDA/NCTR, or Joseph Hanig, Ph.D., FDA/CDER.
Drug-Induced Liver Injury: Interactions Between Drug Properties and Host Factors
Scientists from NCTR, University of Arkansas for Medical Science (UAMS), Hannover Medical School (Germany) and University of Malaga (Spain) have published a review article in the Journal of Hepatologydisclaimer icon that focuses on the multi-faceted interplay between the drug properties, host factors, and drug-host interactions in human drug-induced liver injury (DILI).  The review updates the current knowledge on the physiochemical and toxicological properties of drugs associated with hepatotoxicity, discusses various host factors that may contribute to an individual’s DILI risk, and explores potential drug-host interactions.  Knowledge gaps for future research as well as how to improve risk stratification in patient care were also addressed. 
For additional information, please contact Weida Tong, Ph.D., Director, Division of Bioinformatics and Biostatistics, FDA/NCTR. 

No hay comentarios:

Publicar un comentario